|
|
|
|
| LEADER |
01582nam a2200265 u 4500 |
| 001 |
EB002001325 |
| 003 |
EBX01000000000000001164226 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Aromatase inhibitors in breast cancer
|h Elektronische Ressource
|c Swedish Council on Health Technology Assessment
|
| 260 |
|
|
|a Stockholm
|b Swedish Council on Health Technology Assessment (SBU)
|c 2005, 2005
|
| 300 |
|
|
|a 1 PDF file (2 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Breast Neoplasms
|
| 653 |
|
|
|a Antineoplastic Agents, Hormonal / therapeutic use
|
| 653 |
|
|
|a Aromatase Inhibitors
|
| 710 |
2 |
|
|a Statens beredning för medicinsk utvärdering (Sweden)
|
| 740 |
0 |
2 |
|a Aromatashämmande läkemedel vid bröstcancer
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a SBU alert report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK448005
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a In advanced disease, aromatase inhibitors as first-line therapy have been shown to extend the time to disease progression (strong scientific evidence). Adjuvant therapy with aromatase inhibitors has been shown to reduce the risk for recurrence after followup of approximately 5 years (strong scientific evidence). No scientific evidence is yet available on long-term effects concerning survival and side effects (beyond 5 years). Only limited evidence is available on the cost effectiveness of using aromatase inhibitors
|